An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma-Reference-Cited by-同舟云学术

An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma

Published:2019-03-13 Issue:483 Volume:11 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Sano Renata¹^ORCID,Krytska Kateryna¹,Larmour Colleen E.¹,Raman Pichai²^ORCID,Martinez Daniel³^ORCID,Ligon Gwenda F.⁴,Lillquist Jay S.⁴,Cucchi Ulisse⁵,Orsini Paolo⁵,Rizzi Simona⁵^ORCID,Pawel Bruce R.³^ORCID,Alvarado Diego⁴^ORCID,Mossé Yael P.¹⁶

Affiliation:

1. Division of Oncology and Center for Childhood Cancer Research, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA.

2. Division of Oncology and Center for Biomedical Informatics (CBMi), Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA.

3. Department of Pathology, Children’s Hospital of Philadelphia and Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.

4. Celldex Therapeutics Inc., New Haven, CT 06511, USA.

5. Nerviano Medical Sciences S.r.l., Nerviano (MI) 20014, Italy.

6. Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.

Abstract

ALK is a tractable antibody-drug conjugate target in neuroblastoma.

Funder

U.S. Department of Defense

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference34 articles.